Clinical Trial Update: A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis [Phase 1]

View source ↗

Summary

Phase 1 study evaluating subcutaneously administered tocilizumab in rheumatoid arthritis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED